Introduction
The Ad Hoc Disease Transmission Advisory Committee Monkeypox Summary of Evidence Workgroup (the Workgroup) met via Citrix GoToMeeting teleconference on 10/4/2022 to discuss the following agenda items:

1. Closed Session Case Review
2. Chagas Discussion on Targeted Screening

The following is a summary of the Workgroup’s discussions.

1. **Closed Session Case Review**
The Committee had a closed session review of potential donor-derived transmission events.

2. **Chagas Discussion on Targeted Screening**
The Past Chair presented on criteria for targeted screening for Chagas that will be proposed in January 2023 public comment. He summarized previous Committee discussion and asked if the Committee still agreed that donors born in Latin America (South America, Central America, or Mexico) should be the screening criteria for Chagas. He noted this would exclude donors born in the Caribbean Islands.

CDC recommended testing included:

- Abbott Prism Chagas
- ORTHO T. cruzi ELISA Test System

The Past Chair discussed the pre-test probability and accuracy of these tests. He then suggested the results of these screening tests would need to be available pre-recovery, but CDC confirmatory testing could be available post-recovery if the screening test is positive.

**Summary of discussion:**
Committee members agreed with the proposed criteria for testing and supported its implementation into policy.

**Next steps:**
The Committee will vote on final policy language on November 1, 2022.

3. **Case Review Manual**
The Chair provided an overview of the Case Review Manual drafted by UNOS staff. She explained this was created to better the case review process and help new members in their documentation and adjudication process.
Summary of discussion:
A Committee member asked about NRI (No Recipient Illness) Cases and how many of these cases will come in for malignancies. UNOS staff noted these cases may be the responsibility of leadership until follow-up on these cases is received. The Past Chair flagged the severity definition of ‘potential for late morbidity’ and encouraged the Committee to use it as needed. He suggested that adjudication guidance for Hepatitis B may be helpful for members. Members agreed and suggested the addition for CMV adjudication guidance as well.

A member suggested collating NRI cases to flag cases we expect to have illness versus those that will likely be excluded.

Next steps:
UNOS staff will send out additional case assignments.

Upcoming Meeting
- October 4, 2022, teleconference, 12pm EST
Attendance

- **Committee Members**
  - Ann E. Woodley
  - Anil Trindade
  - Cindy Fisher
  - Dong Lee
  - Emily Blumberg
  - Helen Te
  - Jason D. Goldman
  - Judith Anesi
  - Kelly Dunn
  - Lara Danziger-Isakov
  - Lorenzo Zaffiri
  - Michelle Kittleson
  - R. Patrick Wood
  - Raymund Razonable
  - Ricardo La Hoz
  - Sam Ho
  - Sarah Taimur
  - Stephanie Pouch
  - Timothy Pruett

- **HRSA Representatives**
  - Marilyn Levi
  - Jim Bowman

- **CDC Staff**
  - Sridhar Basavaraju
  - Pallavi Annambhotla
  - Ian Kracalik

- **FDA Staff**
  - Brychan Clark

- **UNOS Staff**
  - Amelia Devereaux
  - Courtney Jett
  - Krissy Laurie
  - Lee Ann Kantos
  - Sandy Bartal
  - Susan Tlusty
  - Taylor Livelli